On 14 July, Moderna scientists published preliminary results of the Phase I clinical trial on its candidate COVID-19 vaccine, mRNA-1273, showing dose-dependent production of antibodies 15 days after vaccination, and mild to moderate adverse effects, such as fever, fatigue, headache, muscle ache, and pain at the injection site. The results were deemed acceptable to advance use of a 100 microgram dose of mRNA-1273 into a Phase III trial in the United States. Moderna and the National Institute of Allergy and Infectious Diseases began a Phase III trial in the United States on 27 July with a plan to enroll and assign 30,000 volunteers to two groups — one group receiving the mRNA-1273 vaccine and the other receiving placebo. As of 7 August, over 4,500 volunteers had enrolled. The test subjects will receive two injections four weeks apart, then wait an additional two weeks for the vaccine to take full effect, then wait to see who catches the virus. According to the Financial Times, Moderna planned to price its vaccine between $50-60 per course.